Cardiovascular disease diagnostic company CardioDx revives IPO plans; updates financials and changes underwriters

By
A A A

CardioDx, which sells diagnostic tests for cardiovascular diseases, revived plans for its upcoming IPO in an amendment filed on Monday. The Palo Alto, CA-based company postponed its IPO in November 2013 citing poor market conditions. The company had previously filed to raise $75 million by offering 5.0 million shares at a range of $14 to $16.

CardioDX, which was founded in 2003 and booked $8 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol CDX. It initially filed confidentially on July 24, 2013. Jefferies and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CDX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

74,282,785
  • $10.84 ▲ 11.64%
60,794,128
  • $17.12 ▲ 0.71%
55,628,662
  • $35.59 ▼ 1.00%
55,306,290
  • $116.47 ▲ 0.14%
55,118,241
  • $39.75 ▼ 0.43%
53,597,648
  • $9.41 ▲ 8.29%
41,889,990
  • $47.98 ▼ 1.48%
35,692,375
  • $97.34 ▼ 0.57%
As of 11/21/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com